Vaccinex Appoints New CMO, Dr. Wagner Departs
Ticker: VCNX · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1205922
| Field | Detail |
|---|---|
| Company | Vaccinex, Inc. (VCNX) |
| Form Type | 8-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-appointment, cmo
TL;DR
Vaccinex swaps CMOs, Wagner out, Ryan in. Big changes for drug pipeline?
AI Summary
On September 10, 2024, Vaccinex, Inc. announced the departure of Dr. Christopher J. Wagner as Chief Medical Officer. The company also appointed Dr. Paul J. P. Ryan as the new Chief Medical Officer, effective September 10, 2024. Additionally, the company reported on its compensatory arrangements for its principal executive officers.
Why It Matters
This filing indicates a change in key leadership within Vaccinex's medical division, which could impact the company's drug development and clinical trial strategies.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can signal shifts in strategy or potential challenges within the company's research and development pipeline.
Key Players & Entities
- Vaccinex, Inc. (company) — Registrant
- Dr. Christopher J. Wagner (person) — Departing Chief Medical Officer
- Dr. Paul J. P. Ryan (person) — Appointed Chief Medical Officer
- September 10, 2024 (date) — Effective date of changes
FAQ
What is the reason for Dr. Christopher J. Wagner's departure as Chief Medical Officer?
The filing does not specify the reason for Dr. Christopher J. Wagner's departure.
What is Dr. Paul J. P. Ryan's background and experience relevant to his new role?
The filing does not provide details on Dr. Paul J. P. Ryan's specific background or experience.
When did Dr. Paul J. P. Ryan's appointment as Chief Medical Officer become effective?
Dr. Paul J. P. Ryan's appointment as Chief Medical Officer became effective on September 10, 2024.
What are the key terms of the compensatory arrangements for the new Chief Medical Officer?
The filing mentions compensatory arrangements for certain officers but does not detail the specific terms for Dr. Paul J. P. Ryan in this excerpt.
Does this filing indicate any changes to Vaccinex's ongoing clinical trials or drug development programs?
While the change in Chief Medical Officer could imply strategic shifts, the filing itself does not explicitly detail changes to ongoing clinical trials or drug development programs.
Filing Stats: 408 words · 2 min read · ~1 pages · Grade level 12.6 · Accepted 2024-09-13 16:16:30
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
Filing Documents
- d806088d8k.htm (8-K) — 22KB
- 0001193125-24-218870.txt ( ) — 137KB
- vcnx-20240910.xsd (EX-101.SCH) — 3KB
- vcnx-20240910_lab.xml (EX-101.LAB) — 17KB
- vcnx-20240910_pre.xml (EX-101.PRE) — 11KB
- d806088d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VACCINEX, INC. Date: September 13, 2024 By: /s/ Jill Sanchez Jill Sanchez Chief Financial Officer